MOTS-c

In cell experiments, MOTS-c slows the folate cycle and the purine building that depends on it. Purines are the chemical building blocks of DNA, RNA and the cell’s energy currency. That shift in the cell’s chemistry leads to the activation of AMPK.

AMPK is the cell’s fuel gauge. When energy runs low, as it does during exercise, AMPK switches on and tells the cell to take up more glucose, burn more fat and make fewer energy-expensive products. In cells and mice, MOTS-c flips that same switch without the workout, a likely reason it improved glucose handling. Whether it does the same when given to people is untested.

In 2018, the same USC group found a second act. Under metabolic stress, such as glucose restriction, MOTS-c travels from the cytoplasm into the cell nucleus, in an AMPK-dependent way. There it regulates a broad set of nuclear genes, including antioxidant response genes, and interacts with NRF2, a master regulator of cellular defense.

That second finding was a first of its kind. Scientists had long known the nucleus controls the mitochondria. MOTS-c was the first factor shown to be coded in mitochondrial DNA and to actively control genes in the nucleus. The two genomes, the authors concluded, talk in both directions.³⁴

Skeletal muscle is one of the body’s main sinks for glucose once insulin rises. When muscle stops responding well to insulin, blood sugar and insulin climb, and the path toward type 2 diabetes begins. That makes muscle the logical target for a metabolic peptide, and in the discovery study it appeared to be MOTS-c’s main target.

In the 2015 Cell Metabolism study, MOTS-c treatment in mice prevented insulin resistance that develops with age and insulin resistance driven by a high-fat diet. It also prevented the weight gain that diet normally causes. These are prevention results, which spare the mice a problem rather than reverse one already there.

A 2024 review in the journal Peptides pulled together work on mitochondrial-derived peptides across type 2 diabetes, type 1 diabetes and gestational diabetes. Its authors noted that the amino acid sequences of these peptides have been conserved through evolution, which suggests they do jobs worth keeping.

What is missing is a human trial testing whether MOTS-c, given as a treatment, improves insulin sensitivity or weight in people. The strongest human evidence comes from a different direction, natural variation in the MOTS-c gene itself.³¹⁰

In 2021, the USC group and collaborators in New Zealand published a study in Nature Communications that tied MOTS-c directly to exercise. In people, exercise raised MOTS-c levels both in skeletal muscle and in the blood. Your muscles make more of this mitochondrial message when you move.

In mice, MOTS-c treatment improved physical performance at three ages, young at two months, middle-aged at twelve months and old at twenty-two months. It regulated nuclear genes for metabolism and protein quality control, changed muscle metabolism and helped muscle cells adapt to metabolic stress.

The most striking result came from the oldest animals. Mice that started intermittent MOTS-c treatment late in life, at about 23.5 months, which is very old for a mouse, gained physical capacity and healthspan. For a field focused on preventing decline, a benefit started this late is unusual.

This is the root of the exercise mimetic label. MOTS-c switches on some of the same machinery exercise does, and exercise raises it. A more accurate reading is that MOTS-c is part of how exercise talks to the body, which makes it a candidate for amplifying training more than for replacing it.⁵

Some of the best human evidence for MOTS-c comes from a single change in mitochondrial DNA. In some people of East Asian descent, one letter in the MOTS-c gene is different, a variant called m.1382A>C. It swaps the 14th amino acid of the peptide, making a version called K14Q that has less biological activity.

A 2021 analysis of three cohorts, 27,527 people in Japan and the United States, found that men carrying this variant had a higher prevalence of type 2 diabetes. Women did not. In one Japanese cohort, J-MICC, the extra risk showed up only in men in the least physically active third.

Mouse work matched the human data. Male mice on a high-fat diet given normal MOTS-c weighed less and handled glucose better. Male mice given the K14Q version did not, and female mice were unaffected either way. The authors described this as a kinesio-genomic interaction, a gene whose effect depends on how much you move.

A related study found that carriers of the same variant had more fast-twitch muscle fibers, and the variant was more common in sprint and power athletes than in endurance athletes. Read together, these studies suggest that MOTS-c shapes how muscle handles fuel, and that physical activity can compensate for a weaker version. That is still a hypothesis, but it comes from human genetics.⁶⁷

Mitochondrial-derived peptides have drawn steady interest from longevity researchers. A 2022 review in the Journal of Clinical Investigation described how these peptides may connect mitochondrial decline to type 2 diabetes, cancer and neurodegenerative disease.

MOTS-c has also been linked to exceptional longevity. In 2015, Japanese and Spanish researchers suggested that the same East Asian variant might be one of the biological factors behind the long lifespans of Japanese people, while noting that more research is needed. That idea sits in some tension with the diabetes finding, which is a reminder of how early this science is.

What the aging research supports so far is a direction. In mice, MOTS-c improved physical capacity even when started late in life, and in people its production responds to exercise. Whether giving MOTS-c to older adults changes how they age has not been tested.

There is a practical reading of this for anyone over 50. In the human data so far, exercise is what raises your own MOTS-c, and the same exercise builds the muscle that MOTS-c acts on. Any decision about adding the peptide is best made on top of that foundation.⁹⁸⁵

MOTS-c has relatives. Humanin and six small humanin-like peptides, called SHLP1 to SHLP6, are coded in the gene for 16S ribosomal RNA. MOTS-c is the only published one coded in the neighboring 12S gene. Together they make up the eight mitochondrial-derived peptides published as of 2022.

Mitochondria read their own genes with a slightly different dictionary, in which some three-letter words that mean stop in the nucleus code for an amino acid, and some that code for an amino acid in the nucleus mean stop. MOTS-c adds a twist: its discoverers reported that it is built outside the mitochondrion using the standard code, even though its gene sits in mitochondrial DNA.

In practice, the family members point in different directions. Humanin was found in a screen for molecules that protect neurons and is studied mostly in brain and metabolic research, largely in animals. MOTS-c is the muscle and exercise peptide of the group, acting directly on how skeletal muscle uses fuel. Both are studied for healthy aging, and neither has published human treatment trials.¹⁰⁹³

Human evidence for MOTS-c falls into two groups. One is physiology, showing that exercise raises MOTS-c in muscle and blood. The other is genetics, showing that a less active version of the peptide tracks with type 2 diabetes in inactive men and with muscle fiber type.

Neither is a treatment trial. No peer-reviewed study has yet reported what happens when people are given MOTS-c, how it affects insulin sensitivity or body weight, or how safe it is over months. FDA’s April 2026 compounding page noted the absence of human exposure data.

It is also fair to know who did the work. Much of the MOTS-c research comes from one USC-centered network, and several authors disclose consulting roles and stock in CohBar, the company to which UCLA licensed intellectual property on humanin, MOTS-c and the SHLPs. That does not undo the findings, which appeared in leading journals, but independent replication matters.⁵⁶⁷¹²⁹

Because MOTS-c has no published human safety trials, its side effects in people are unknown. FDA’s April 2026 compounding page made the same point. The mouse study abstracts do not describe harms, but those studies were not designed to look for them.

One theoretical concern follows from the mechanism, though it has not been studied in people. A peptide that improves how muscle clears glucose could add to the effect of insulin, sulfonylureas or other glucose-lowering medicines. Anyone taking them should involve their prescribing clinician and monitor blood sugar.

Quality is the other practical risk. Compounded MOTS-c from a licensed 503A pharmacy is a different product from a vial sold online for research use. People who should talk to a clinician first include anyone on diabetes medicine, anyone pregnant or breastfeeding, anyone with kidney or liver disease, and tested athletes.¹²³¹⁰

MOTS-c is studied for how the body handles glucose, so the useful labs measure that system. HbA1c reflects your average blood sugar over about three months, which makes it useful general context on long-term glucose. No validated protocol uses it to judge whether MOTS-c helps.

Fasting insulin often rises years before fasting glucose does, because the pancreas works harder to keep sugar normal as muscle becomes resistant. Paired with fasting glucose, it can estimate insulin resistance, though those estimates have limits and are not a test for selecting or monitoring MOTS-c. ALT, a liver enzyme, adds general context on liver health, since the liver also handles glucose and fat.

This is how Vitals Vault approaches peptide care. A blood panel at Quest Diagnostics comes first, a licensed clinician reviews your results and history and decides whether MOTS-c fits, and the course ends with a retest of the same markers.³

On October 29, 2026, NCPA reported that FDA granted enforcement discretion allowing 503A compounding pharmacies to prepare MOTS-c, along with five other peptides, for individual patients with a prescription. There is no end date, and final rulemaking is pending. MOTS-c is still not an FDA-approved drug.

Athletes face a stricter rule. The World Anti-Doping Agency’s 2026 Prohibited List names MOTS-c as an AMPK activator under metabolic modulators, prohibited in and out of competition.¹¹¹²¹⁴

MOTS-c is a message from your mitochondria to your muscles, coded in DNA your mother passed down and released when you exercise. In mice it prevents insulin resistance and weight gain and keeps aging animals more capable. In people, genetics and exercise studies suggest it matters, but no published trial has tested it as a treatment.

If you are considering it, the sharper question is how much of what MOTS-c does you are already getting. Regular training raises your own MOTS-c, and the genetic data hint that movement can make up for a weaker version. A clinician can look at your metabolic health and the proven options first, though no test can tell you in advance whether MOTS-c would add anything on top.³⁵⁶